Compare FTCI & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTCI | XGN |
|---|---|---|
| Founded | 2017 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.4M | 110.4M |
| IPO Year | 2021 | 2014 |
| Metric | FTCI | XGN |
|---|---|---|
| Price | $5.04 | $4.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $10.80 | $8.86 |
| AVG Volume (30 Days) | 90.5K | ★ 381.2K |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,687,000.00 | N/A |
| Revenue This Year | $65.44 | $8.12 |
| Revenue Next Year | $45.97 | $13.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 110.51 | N/A |
| 52 Week Low | $3.21 | $2.59 |
| 52 Week High | $12.75 | $12.23 |
| Indicator | FTCI | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 54.09 | 53.58 |
| Support Level | $4.20 | $4.11 |
| Resistance Level | $5.31 | $5.55 |
| Average True Range (ATR) | 0.48 | 0.40 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 45.98 | 23.61 |
FTC Solar Inc is a provider of solar tracker systems, supported by proprietary software and value-added engineering services. The company's Solar tracker systems move solar panels throughout the day to maintain an optimal orientation relative to the sun, thereby increasing the amount of solar energy produced at a solar installation. It focuses on providing differentiated products, software, and services that maximize energy generation. The company has launched a new mounting solution to support the installation and use of U.S. manufactured thin-film modules by project owners. The only segment the company is engaged in is the Manufacturing and Servicing of Solar tracker systems.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.